Related Experiment Videos
Marrow transplantation for thalassemia
Bone Marrow Transplantation
|December 1, 1986
Summary
Bone marrow transplantation can cure beta thalassemia in children. However, successful engraftment is less likely in heavily transfused patients or those receiving non-HLA-identical marrow.
Area of Science:
- Hematology
- Pediatric Hematology
- Transplantation Medicine
Background:
- Beta thalassemia is a severe inherited blood disorder.
- Bone marrow transplantation (BMT) is a potential curative therapy.
- Patient factors can influence BMT outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of BMT in pediatric patients with homozygous beta thalassemia.
- To identify factors affecting engraftment and survival post-BMT.
Main Methods:
- Ten pediatric patients with homozygous beta thalassemia underwent BMT from related donors.
- Conditioning regimens varied, including busulfan, cyclophosphamide, and total body irradiation.
- Engraftment, survival, and complications were monitored.
Main Results:
- Seven of ten patients survived beyond 170 days post-transplant.
- Three patients achieved durable engraftment, while four had autologous recovery.
- Engraftment was significantly higher in patients with fewer than 50 prior transfusions (P < 0.05).
- Six-month actuarial survival was 80%, with 40% disease-free survival.
Conclusions:
- BMT can be a curative option for pediatric beta thalassemia.
- Prior transfusion history and HLA compatibility are critical factors for successful engraftment.
- Further research is needed to optimize BMT protocols for heavily transfused patients.